02076nam a2200385Ia 4500001001200000003000600012005001700018007001400035008004100049020001500090020001800105040006500123043001200188074001900200086002200219088008900241110009800330245027100428246006800699260008500767300004400852336002600896337002700922338003100949500006700980500003601047500002501083500002501108504004101133533009301174650004901267650005801316776015901374776015701533ocm55983220OCoLC20180706132118.0he bmb024bbca040721s2004    dcua    bb   f000 0 eng d  a0160717140  a9780160717147  aPUCPRbengcFPSdOCLCQdOCLCOdOCLCQdOCLCAdOCLCFdGPOdMvI  an-us---  a1019-B-01 (MF)0 aY 4.C 73/8:108-73  aSerial no. 108-73 (United States. Congress. House. Committee on Energy and Commerce)1 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Health.10aPrescription drug monitoring :bstrategies to promote treatment and deter prescription drug use : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighth Congress, second session, March 4, 2004.30aStrategies to promote treatment and deter prescription drug use  aWashington :bU.S. G.P.O. :bFor sale by the Supt. of Docs., U.S. G.P.O.,c2004.  aiii, 73 pages :billustrations ;c24 cm  atextbtxt2rdacontent  amicroformbh2rdamedia  amicrofichebhe2rdacarrier  a"Printed for the use of the Committee on Energy and Commerce."  aShipping list no.: 2004-0382-M.  a"Serial no. 108-73."  aCRDP Program record.  aIncludes bibliographical references.  aMicrofiche.bWashington :cSupt. of Docs., U.S. G.P.O.,d2004.e1 microfiche : negative. 0aMedication abusezUnited StatesxPrevention. 0aMedication abusexLaw and legislationzUnited States.08iOnline version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tPrescription drug monitoringw(OCoLC)68049412708iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tPrescription drug monitoringw(OCoLC)55688393